Mereo BioPharma (MREO) Equity Average (2018 - 2026)

Mereo BioPharma (MREO) has 5 years of Equity Average data on file, last reported at $37.5 million in Q1 2026.

• Equity Average for Q1 2026 came in at $37.5 million, down 38.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $37.5 million (down 38.07% YoY), and the FY2025 annual result was $50.9 million, down 8.63% from the prior year.
• Equity Average eased to $37.5 million in Q1 2026 per MREO's latest filing, from $43.8 million in the prior quarter.
• Over five years, Equity Average peaked at $60.7 million in Q2 2024 and troughed at -$5.8 million in Q4 2024.
• A 4-year average of $42.6 million and a median of $47.9 million in 2023 frame the typical range for Equity Average.
• The sharpest annual moves came in 2024 and 2025: Equity Average slumped 110.99% in 2024, then jumped 1548.27% in 2025.
• A 4-year view of Equity Average shows it stood at $52.6 million in 2023, then tumbled by 110.99% to -$5.8 million in 2024, then jumped by 856.58% to $43.8 million in 2025, then fell by 14.33% to $37.5 million in 2026.
• Business Quant data shows MREO's Equity Average at $37.5 million in Q1 2026, $43.8 million in Q4 2025, and $50.4 million in Q3 2025.